Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder
- 1 March 1991
- journal article
- clinical trial
- Published by Elsevier in Biological Psychiatry
- Vol. 29 (5), 418-426
- https://doi.org/10.1016/0006-3223(91)90264-m
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- m-CPP: a tool for studying behavioural responses associated with 5-HT1c receptorsTrends in Pharmacological Sciences, 1990
- Involvement of 5-HT1C-receptors in drug-induced penile erections in ratsPsychopharmacology, 1990
- 5-HT1C receptor activation: a key step in the initiation of migraine?Trends in Pharmacological Sciences, 1989
- Efficacy of Fluvoxamine in Obsessive-Compulsive DisorderArchives of General Psychiatry, 1989
- Clomipramine in Obsessive-Compulsive DisorderArchives of General Psychiatry, 1989
- Serotonergic and noradrenergic sensitivity in obsessive-compulsive disorder: behavioral findingsAmerican Journal of Psychiatry, 1988
- Evidence that mCPP may have behavioural effects mediated by central 5‐HT1C receptorsBritish Journal of Pharmacology, 1988
- Serotonin Function in Obsessive-Compulsive DisorderArchives of General Psychiatry, 1988
- Functional Correlates of Serotonin 5-HT1Recognition SitesJournal of Receptor Research, 1988
- (—)-m-Chlorophenyl-piperazine, a central 5-hydroxytryptamine agonist, is a metabolite of trazodoneJournal of Pharmacy and Pharmacology, 1981